Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Protalix ( (PLX) ) has provided an update.
On July 21, 2025, Protalix BioTherapeutics announced the appointment of Gilad Mamlok as the new Senior Vice President and Chief Financial Officer, effective August 24, 2025, succeeding Eyal Rubin. Mamlok, with three decades of experience in healthcare and technology sectors, is expected to play a crucial role in executing Protalix’s growth strategy. The transition is designed to be seamless with Rubin assisting until October 2025. This leadership change is anticipated to strengthen Protalix’s financial and operational strategies, further solidifying its position in the biopharmaceutical industry.
The most recent analyst rating on (PLX) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Protalix stock, see the PLX Stock Forecast page.
Spark’s Take on PLX Stock
According to Spark, TipRanks’ AI Analyst, PLX is a Neutral.
Protalix’s stock is supported by improving financial performance and positive developments in its earnings call. However, technical indicators suggest caution, and valuation metrics are moderate. The company’s ability to sustain revenue growth while managing costs will be crucial for future performance.
To see Spark’s full report on PLX stock, click here.
More about Protalix
Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins using its proprietary ProCellEx plant cell-based expression system. It is notable for being the first company to gain FDA approval for a protein produced through a plant cell-based suspension expression system. Protalix has partnered with Pfizer for the global development of taliglucerase alfa for Gaucher disease, and with Chiesi Farmaceutici for the development of Elfabrio, which was approved by the FDA and EMA in 2023.
Average Trading Volume: 1,137,357
Technical Sentiment Signal: Strong Sell
Current Market Cap: $115.4M
Find detailed analytics on PLX stock on TipRanks’ Stock Analysis page.